REQUIP
Pronunciation: roe-PIN-i-roel (REE-kwip)


What it isNon-ergot D2/D3 dopamine agonist; Parkinson disease and restless legs syndrome.
Why this oneUnlike pramipexole, it is cleared hepatically through CYP1A2, making renal impairment less limiting.
What limits itAsk directly about gambling, shopping, hypersexuality, and sudden sleep; hallucinations and orthostasis also limit use.
Animated chart of estimated U.S. prescriptions per year, Parkinson medicines (1948–2026). Ropinirole enters in 1997 (estimated).
Principal riskImpulse-control disorders and sudden sleep onset
Legacy pregnancy categoryC
Defining liabilityOrthostasis, hallucinations, dyskinesia and impulse-control symptoms; abrupt withdrawal can be hazardous.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Parkinson's disease | Adults | 0.25 mg TID | titrate to response | 24 mg/day (8 mg TID); ESRD on hemodialysis 18 mg/day |
| Restless legs syndrome | Adults | 0.25 mg QD (1–3 h before bedtime) | titrate to response | 4 mg/day; ESRD on hemodialysis 3 mg/day |
Titration PD: increase at weekly intervals. RLS: increase after 2 days, then at weekly intervals.
Renal Moderate (CrCl 30–50): no adjustment. ESRD on hemodialysis: max 18 mg/day (PD), 3 mg/day (RLS); no post-dialysis supplement. Severe without dialysis: not studied.
Hepatic Undefined
Available strengths
Pregnancy No adequate human data; animal data show fetal harm (teratogenicity, embryolethality).
Lactation Undefined
Generic entry2008
Open Ropinirole in the interactive console ↗

Open Ropinirole in the interactive console ↗